论文部分内容阅读
目的:观察金龙胶囊对晚期非小细胞肺癌(advancedNon-SmallCellLungCancer,ANSCLC)患者的CD4/CD8、自然杀伤细胞(NaturalKillercell,NK细胞)活性的影响。方法:89例非小细胞肺癌患者分治疗组49例和对照组40例,两组以顺铂、依托泊苷(EP)方案或紫杉醇、顺铂(TP)方案化学药物治疗(化疗)至少2个疗程。治疗组在化疗开始同时给予金龙胶囊4粒,每日3次口服,连服8周为1个疗程。所有病例在化疗前及第2个疗程结束后第15日检查CD4/CD8、NK细胞的活性。结果:治疗组治疗前后CD4/CD8分别为(1.2±0.3)和(1.5±0.4)(P<0.05),NK细胞活性分别为(27±9)和(32±10)(P<0.05);对照组相应为(1.2±0.3)和(1.2±0.2),(25±8)和(24±8)(均为P>0.05)。结论:金龙胶囊能增强晚期非小细胞肺癌患者的免疫水平。
Objective: To observe the effect of Jinlong Capsule on the activity of CD4 / CD8 and Natural Killer Cell (NK) cells in patients with advanced non small cell lung cancer (ANSCLC). Methods: Ninety - nine patients with non - small cell lung cancer were divided into treatment group (n = 49) and control group (n = 40). The two groups were treated with cisplatin or etoposide (EP) or paclitaxel and cisplatin (TP) A course of treatment. In the treatment group, 4 capsules of Jinlong Capsule were given at the same time of chemotherapy, 3 times a day orally, even for 8 weeks for 1 course of treatment. All cases were tested for CD4 / CD8, NK cell activity before chemotherapy and on the 15th day after the second course of treatment. Results: Before and after treatment, the CD4 / CD8 ratio in the treatment group was (1.2 ± 0.3) and (1.5 ± 0.4), respectively. The NK cell activity was (27 ± 9) and (32 ± 10) The controls were (1.2 ± 0.3) and (1.2 ± 0.2), (25 ± 8) and (24 ± 8), respectively (all P> 0.05). Conclusion: Jinlong Capsule can enhance the immune level of patients with advanced non-small cell lung cancer.